Urothelial cancer
61 – 70 of 119
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2022
-
Mark
Reply to Joep J. de Jong and Ewan A. Gibb's Letter to the Editor re: Gottfrid Sjödahl, Johan Abrahamsson, Karin Holmsten, et al. Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes. Eur Urol. 2022;81:316-7. Neoadjuvant Chemotherapy Response in Muscle-invasive Bladder Cancer: Differences in Intrinsic Biology or Subtyping Nomenclature?
(
- Contribution to journal › Letter
-
Mark
Molecular pathology of the non-luminal Ba/Sq-like and Sc/NE-like classes of urothelial tumours : An integrated immunohistochemical analysis
(
- Contribution to journal › Article
-
Mark
Molecular Subtypes as a Basis for Stratified Use of Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer—A Narrative Review
(
- Contribution to journal › Scientific review
-
Mark
Swedish National Guidelines on Urothelial Carcinoma : 2021 update on non-muscle invasive bladder cancer and upper tract urothelial carcinoma
(
- Contribution to journal › Article
-
Mark
Cost Effectiveness of the Use of Prophylactic Mesh To Prevent Parastomal Hernia After Urinary Diversion with an Ileal Conduit
(
- Contribution to journal › Article
-
Mark
Robot-assisted nephroureterectomy for upper tract urothelial carcinoma—feasibility and complications : a single center experience
(
- Contribution to journal › Article
-
Mark
Restoring tumor immunogenicity with dendritic cell reprogramming
(
- Contribution to journal › Published meeting abstract
-
Mark
Immunohistochemical Assays for Bladder Cancer Molecular Subtyping : Optimizing Parsimony and Performance of Lund Taxonomy Classifiers
(
- Contribution to journal › Article
- 2021
-
Mark
Association Between Estrogen Receptors and GATA3 in Bladder Cancer : A Systematic Review and Meta-Analysis of Their Clinicopathological Significance
(
- Contribution to journal › Scientific review
-
Mark
Urinary diversions for benign and oncologic indications: what did we learn about short term complications in the last 24 months?
(
- Contribution to journal › Article